First biosimilar monoclonal antibody approved in Europe


"approved" green key on keyboard

The Generic Medicines Industry Association has welcomed the announcement from member company, Hospira, that its biosimilar infliximab (Inflectra) is now available in more major European markets, including Austria, Denmark, France, Germany, Greece, Italy, Luxembourg, Netherlands, Spain and Sweden.



This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Register here

Forgot Password?

Previous Prof services should go under MBS, not 6CPA: CHF
Next QUM, primary care, compliance key issues: NPS MedicineWise

NOTICE: It can sometimes take awhile for comment submissions to go through, please be patient.